Mirae Asset Capital Life Science
Mirae Asset Capital Life Science is a venture capital firm established in 2023, specializing in providing financial solutions for companies focused on life sciences. With investment professionals based in Boston and San Francisco, the firm targets therapeutics companies at various stages of development, from seed funding to Series C rounds. Mirae Asset Capital Life Science aims to support innovative companies that prioritize advancements in life science, contributing to the growth and evolution of the industry.
Top Stages
2 past transactions
Attovia Therapeutics
Series C in 2025
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Accent Therapeutics
Series C in 2024
Accent Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for oncology, utilizing the emerging field of epitranscriptomics. Founded in 2017 and headquartered in Lexington, Massachusetts, the company explores the post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting cancer-associated RNA-modifying proteins, Accent Therapeutics aims to innovate and deliver transformative therapies that can significantly improve patient outcomes in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.